N Harbeck
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
Müller V, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T, Hoffmann O, Rübner M, Huober J, Banys-Paluchowski M, Friedl T, Fasching P, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, DETECT study group. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open 2021; 6:100299.
25.11.2021Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
25.11.2021ESMO Open 2021; 6:100299
Müller V, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T, Hoffmann O, Rübner M, Huober Jens, Banys-Paluchowski M, Friedl T W P, Fasching P A, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, DETECT study group
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Xu B, Osborne K, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Khaled H, Huober J, Huang C, Hayes D, Harbeck N, Pagani O, Partridge A, Pritchard K, Whelan T, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E, Ro J, Goodwin P, Gulluoglu B, André F, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsky P, Gnant M, Winer E, Burstein H, Baselga J, Bergh J, Bonnefoi H, Garber J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Brucker S, Curigliano G. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2018; 29:2153.
01.10.2018De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
01.10.2018Ann Oncol 2018; 29:2153
Xu B, Osborne K C, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Khaled H, Huober J, Huang C-S, Hayes D F, Harbeck N, Pagani O, Partridge A H, Pritchard K, Whelan T J, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E J T, Ro J, Goodwin P, Gulluoglu B, André F, Thürlimann Beat, Senn H-J, Piccart-Gebhart M, Regan M M, Colleoni M, Loibl S, Dubsky P, Gnant M, Winer E P, Burstein H J, Baselga J, Bergh J, Bonnefoi H, Garber J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Brucker S Y, Curigliano G
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
Möbus V, Kurbacher C, Untch M, Konecny G, Hinke A, Runnebaum I, von Minckwitz G, Harbeck N, Huober J, Schneeweiss A, Nitz U, Kuhn W, Thomssen C, du Bois A, Lück H, Jackisch C, AGO Breast Study Group (AGO-B). Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. Ann Oncol 2018; 29:178-185.
01.01.2018Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
01.01.2018Ann Oncol 2018; 29:178-185
Möbus V, Kurbacher C, Untch M, Konecny G E, Hinke A, Runnebaum I B, von Minckwitz G, Harbeck N, Huober Jens, Schneeweiss A, Nitz U, Kuhn W, Thomssen C, du Bois A, Lück H J, Jackisch C, AGO Breast Study Group (AGO-B)
Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al
Xu B, Osborne K, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Khaled H, Huober J, Huang C, Hayes D, Harbeck N, Pagani O, Partridge A, Pritchard K, Whelan T, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsky P, Gnant M, Winer E, Burstein H, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Brucker S, Bonnefoi H, Curigliano G. Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al. Ann Oncol 2017
25.09.2017Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al
25.09.2017Ann Oncol 2017
Xu B, Osborne K C, Orecchia R, Morrow M, Karlsson Per, Jiang Z, Jassem J, Khaled H, Huober J, Huang C-S, Hayes D F, Harbeck N, Pagani O, Partridge A H, Pritchard K, Whelan T J, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E J T, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann Beat, Senn H-J, Piccart-Gebhart M, Regan M M, Colleoni M, Loibl S, Dubsky P, Gnant M, Winer E P, Burstein H J, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Brucker S Y, Bonnefoi H, Curigliano G
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Xu B, Osborne K, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Hussein K, Huober J, Huang C, Hayes D, Harbeck N, Pagani O, Partridge A, Pritchard K, Whelan T, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsky P, Gnant M, P Winer E, Burstein H, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Y Brucker S, Bonnefoi H, Curigliano G. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28:1700-1712.
01.08.2017De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
01.08.2017Ann Oncol 2017; 28:1700-1712
Xu B, Osborne K C, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Hussein K, Huober J, Huang C-S, Hayes D F, Harbeck N, Pagani O, Partridge A H, Pritchard K, Whelan T J, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E J T, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann Beat, Senn H-J, Piccart-Gebhart M, Regan M M, Colleoni M, Loibl S, Dubsky P, Gnant M, P Winer E, Burstein H J, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Y Brucker S, Bonnefoi H, Curigliano G
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
Möbus V, Thomssen C, Untch M, Nekljudova V, Loibl S, du Bois A, Bauerfeind I, Müller V, Huober J, Fehm T, Conrad B, Harbeck N, Elling D, Tesch H, Schneeweiss A, Lück H, Jackisch C, von Minckwitz G, German Breast Group (GBG), the AGO Breast Study Group (AGO-B) and NOGGO Study Groups. German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients. Ann Oncol 2017; 28:1803-1810.
01.08.2017German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
01.08.2017Ann Oncol 2017; 28:1803-1810
Möbus V, Thomssen C, Untch M, Nekljudova V, Loibl S, du Bois A, Bauerfeind I, Müller V, Huober Jens, Fehm T, Conrad B, Harbeck N, Elling D, Tesch H, Schneeweiss A, Lück H-J, Jackisch C, von Minckwitz G, German Breast Group (GBG), the AGO Breast Study Group (AGO-B) and NOGGO Study Groups
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober J, Kreipe H, Kates R, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol 2017; 28:2899.
01.01.2017Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
01.01.2017Ann Oncol 2017; 28:2899
Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober Jens, Kreipe H H, Kates R E, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W
Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study
Janni W, Friedl T, Zwingers T, Huober J, Scholz C, Annecke K, Wischnik A, Jueckstock J, Augustin D, Rack B, Harbeck N, Kiechle M. Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study. Br J Cancer 2016; 114:863-71.
31.03.2016Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study
31.03.2016Br J Cancer 2016; 114:863-71
Janni W, Friedl T W P, Zwingers T, Huober Jens, Scholz C, Annecke K, Wischnik A, Jueckstock J, Augustin D, Rack B, Harbeck N, Kiechle M
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial
Gluz O, Augustin D, Hoffmann G, Thomssen C, Jänicke F, Kiechle M, Wallwiener D, Kuhn W, Nitz U, Möbus V, Mohrmann S, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates R, Kreipe H, Hartmann A, Pelz E, Erber R, Harbeck N. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. Ann Oncol 2016; 27:1035-1040.
18.02.2016Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial
18.02.2016Ann Oncol 2016; 27:1035-1040
Gluz O, Augustin D, Hoffmann G, Thomssen C, Jänicke F, Kiechle M, Wallwiener D, Kuhn W, Nitz U, Möbus V, Mohrmann S, Liedtke C, Huober Jens, Peyro-Saint-Paul H, Kates R E, Kreipe H H, Hartmann A, Pelz E, Erber R, Harbeck N
Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel
Hadji P, Gnant M, Gray R, Harbeck N, Thürlimann B, Untch M, Cortes J, Martin M, Albert U, Conte P, Ejlertsen B, Bergh J, Kaufmann M, Smith I, Dodwell D, Coleman R, Wilson C, Powles T, Clézardin P, Aapro M, Costa L, Body J, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D, Holen I. Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel. Ann Oncol 2015
17.12.2015Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel
17.12.2015Ann Oncol 2015
Hadji P, Gnant M, Gray R, Harbeck N, Thürlimann Beat, Untch M, Cortes J, Martin M, Albert U-S, Conte P-F, Ejlertsen B, Bergh J, Kaufmann M, Smith I, Dodwell D, Coleman R E, Wilson C, Powles T J, Clézardin P, Aapro M, Costa L, Body J-J, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D, Holen I
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)
Untch M, Blohmer J, Costa S, Decker T, Diel I, Fasching P, Fehm T, Janni W, Lück H, Maass N, Scharl A, Beckmann M, Jackisch C, Thomssen C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe H, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Loibl S. Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015). Geburtshilfe Frauenheilkd 2015; 75:556-565.
17.06.2015Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)
17.06.2015Geburtshilfe Frauenheilkd 2015; 75:556-565
Untch M, Blohmer J-U, Costa S-D, Decker T, Diel I, Fasching P A, Fehm T, Janni W, Lück H-J, Maass N, Scharl A, Beckmann M W, Jackisch C, Thomssen C, Harbeck N, Huober Jens, von Minckwitz G, Gerber B, Kreipe H-H, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Loibl S
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober J, Kreipe H, Kates R, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol 2014; 25:1551-7.
14.05.2014Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
14.05.2014Ann Oncol 2014; 25:1551-7
Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober Jens, Kreipe H H, Kates R E, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial
Huober J, Nimmrich I, May C, Beckmann M, Baumgärtner A, Kubista E, Ragosch V, Azim H, Paepke S, Reimer T, Thomssen C, Wallwiener D, Petruzelka L, Barsoum M, Fasching P, Harbeck N. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast 2011; 21:27-33.
08.09.2011Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial
08.09.2011Breast 2011; 21:27-33
Huober Jens, Nimmrich I, May C, Beckmann M W, Baumgärtner A K, Kubista E, Ragosch V, Azim H A, Paepke S, Reimer T, Thomssen C, Wallwiener D, Petruzelka L, Barsoum M, Fasching P A, Harbeck N
Translationale Forschung beim Mammakarzinom- Workshop zur Erarbeitung neuer Forschungsideen im Rahmen des Biedenkopfsymposiums Xlll der Banss-Stiftung
von Minkwitz G, Thomssen C, Schrauder M, Roller M, Rody A, Niederacher D, Müller M, Martin B, Loibl S, Lenhard M, Momor M, Karn T, Huober J, Harbeck N, Groner B, Eidtmann H, Kaufmann M. Translationale Forschung beim Mammakarzinom- Workshop zur Erarbeitung neuer Forschungsideen im Rahmen des Biedenkopfsymposiums Xlll der Banss-Stiftung. Geburtsh Frauenheilk 2008; 68:1160-1165.
01.01.2008Translationale Forschung beim Mammakarzinom- Workshop zur Erarbeitung neuer Forschungsideen im Rahmen des Biedenkopfsymposiums Xlll der Banss-Stiftung
01.01.2008Geburtsh Frauenheilk 2008; 68:1160-1165
von Minkwitz G, Thomssen C, Schrauder M, Roller M, Rody A, Niederacher D, Müller M, Martin B, Loibl S, Lenhard M, Momor M, Karn T, Huober Jens, Harbeck N, Groner B, Eidtmann H, Kaufmann M
Überblick über die neoadjuvante endokrine Theraphie des rezeptorpositiven Mammakarzinoms der postmenopausalen Frau
Paepke S, Eiermann W, Wolf C, Huober J, Warm M, Blohmer J, Diedrich F, Fischer T, Pildner v Steinburg S, Schwarz-Böger U, Jacobs V, Harbeck N, Kiechle M. Überblick über die neoadjuvante endokrine Theraphie des rezeptorpositiven Mammakarzinoms der postmenopausalen Frau. Geburtsh Frauenheilk 2004; 64:1290-1298.
01.01.2004Überblick über die neoadjuvante endokrine Theraphie des rezeptorpositiven Mammakarzinoms der postmenopausalen Frau
01.01.2004Geburtsh Frauenheilk 2004; 64:1290-1298
Paepke S, Eiermann W, Wolf C, Huober Jens, Warm M, Blohmer J, Diedrich F, Fischer T, Pildner v Steinburg S, Schwarz-Böger U, Jacobs VR, Harbeck N, Kiechle M